You are here

Prices & Quotes - UK Markets - Johnson Matthey (JMAT)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Share Price:
Up 3,186.00p
Change Today:
14.00p
Market Cap:
6,338m
Sector:
Chemicals

Sunday share tips: Ergomed, Johnson Matthey

By Alexander Bueso

Date: Sunday 06 Dec 2020

LONDON (ShareCast) - (Sharecast News) - The Mail on Sunday's Midas column recommended readers 'buy' shares of pharmacovigilance specialist Ergomed.
All drugs, even already tried and tested ones, such as aspirin, are monitored on an ongoing basis to monitor their continued safety.

That certainly also applies to new ones, such as the Covid-19 vaccines whose rollout is imminent.

Critically, that is not because they are deemed unsafe, it is simply a matter of medical 'best practice' and Ergomed is a leader in the field, the tipster explained.

As well, in a typical year, hundreds of clinical trials take place which require firms capable of organising the entire process and most trials take several years to complete.

Ergomed's founder, Miroslav Reljanovic, has strengthened has strengthened the management team over the past two years and is looking to continue expanding.

Its finance chief, Richard Barfield, is another experienced hand and has a track record of success at other firms within the same sector, having pursued of both organic and inorganic growth, which Ergomed is likely to follow, Midas added.

Sales are expected to grow 14% in 2020 to reach 85m alongside a 58% surge in profits to 14.6m, with further "substantial" gains likely in the year ahead, according to analysts.

"Ergomed shares have done well this year, benefiting from increased investor interest in almost all healthcare stocks.

"However, the company is profitable, its balance sheet is robust and the shares should continue to rise as Reljanovic and Barfield roll out their strategy. Buy."



The Sunday Times's John Collingridge believes shares of specialty chemicals maker Johnson Matthey are best avoided.

Writing in the newspaper's 'Inside the City' column, the tipster cited the Prime Minister's move to bring forward the ban on the sale of new petrol and diesel cars by five years to 2030 as the reason.

Catalytic converters account for roughly 60% of the manufacturer's sales and over half its profits.

Yes, the engineer had been shifting towards less endangered markets but the process was like turning an oil tanker, he added.

Johnson Matthey rival Umicore had moved more quickly to dodge the extinction threat by investing heavily in battery materials.

And while the company was now also moving into batteries, as well as hydrogen, analysts at Investec judge that it is "well behind its peers" on the former, not to mention the costs of scaling up its battery materials factory in Poland.

"The company must show that car giants share its enthusiasm for its battery technology by signing up some big names. If not, investors may lose patience.

"An activist could emerge to insist on running the business for cash, or a break-up. In its current form, it risks falling behind in the race to zero emissions. Avoid."

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Johnson Matthey Market Data

Currency UK Pounds
Price 3,186.00p
Change Today 14.00p
52 Week High 3,300.00p
52 Week Low 1,845.50p
Volume 514,622
Shares Issued 198.94m
Market Cap 6,338m
Beta 0.00

Performance Indicators

Compare performance with the sector and the market.

Key
Vs Market
Vs Sector
Value
market
  1. full market star
  2. full market star
  3. full market star
  4. half market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. full sector star
Price Trend
market
  1. full market star
  2. full market star
  3. half market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. empty sector
  4. empty sector
  5. empty sector
Income
market
  1. full market star
  2. full market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. empty sector
Growth
market
  1. full market star
  2. full market star
  3. half market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. empty sector
Price Chg 6m
market
  1. full market star
  2. full market star
  3. full market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector
P/E
market
  1. full market star
  2. full market star
  3. full market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. full sector star
PEG
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. empty sector
Dividend Yield
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. empty sector
  5. empty sector
EPS Growth
market
  1. full market star
  2. full market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. empty sector
  4. empty sector
  5. empty sector
Operating Margin
market
  1. full market star
  2. full market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector

What The Brokers Say

Strong Buy 7
Buy 1
Neutral 7
Sell 2
Strong Sell 3
Total 20
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Johnson Matthey Dividends

  Latest Previous
  Interim Final
Ex-Div 26-Nov-20 18-Jun-20
Paid 04-Feb-21 04-Aug-20
Amount 20.00p 31.12p

Trades for 16-Apr-2021

Time Volume / Share Price
16:35 247,584 @ 3,186.00p
16:29 32 @ 3,180.00p
16:29 75 @ 3,180.00p
16:29 39 @ 3,180.00p
16:29 36 @ 3,180.00p

Johnson Matthey Key Personnel

CEO Robert MacLeod
Chair Patrick W. Thomas
CFO Stephen Oxley